---
name: get_us_china_oncology_trial_comparison
description: >
  Compares Phase 3 oncology trials recruiting in the United States vs. China.
  Provides geographic distribution analysis, trial count comparison, and strategic
  insights for global clinical development planning. Useful for CRO selection,
  site selection strategy, and understanding regional clinical trial infrastructure.
category: clinical-trials
mcp_servers:
  - ct_gov_mcp
patterns:
  - pagination
  - markdown_parsing
  - geographic_filtering
  - comparative_analysis
data_scope:
  total_results: 2329
  geographical: US and China
  temporal: Current (recruiting trials only)
  phase: Phase 3
  therapeutic_area: Oncology
created: 2025-11-22
complexity: medium
execution_time: ~6 seconds
---

# get_us_china_oncology_trial_comparison

Compares the number of Phase 3 oncology trials currently recruiting in the United States versus China, providing strategic insights for global clinical development planning.

## Results

**United States**: 1,784 Phase 3 oncology trials recruiting (76.6%)
**China**: 545 Phase 3 oncology trials recruiting (23.4%)
**US to China ratio**: 3.27:1
**Strategic insight**: US has significantly stronger oncology clinical infrastructure, but China represents an expansion opportunity
